Methyl jasmonate ameliorates rotenone-induced motor deficits in rats through its neuroprotective activity and increased expression of tyrosine hydroxylase immunopositive cells
Decreased tyrosine hydroxylase (TH) activity, due to degeneration of dopaminergic neurons contributes to the low dopamine content and the motor deficits that characterized Parkinson’s disease (PD). This study examines the effect of methyl jasmonate (MJ), a neuroprotective bioactive compound isolated from jasminum grandiflorum, on motor functions, immunopositive cells of TH, dendritic neurons and dopamine contents in rotenone (Rot)-treated rats. Rats pretreated daily with MJ (100 mg/kg, i.p) for 21 days also received Rot (2.5 mg/kg, i.p.) 30 min after each pretreatment for every 48 h for 21 days. Motor functions were assessed on day 22. The specific brain regions of the rats were processed for determination of dopamine contents, immunopositive cells of TH, neuronal cell morphology and dendritic aborizations. Rot impaired locomotion and rearing behavior, and decreased dopamine content in the striatum, prefrontal cortex and midbrain. It further reduced the expression of TH in the substantia nigra and striatum relative to vehicle-control (p < 0.05). Histopathologic studies revealed that Rot-treated rats had degenerated neurons with pyknotic nuclei and loss of nigrostriatal neuronal cells. Rot also altered the nigrostriatal dendritic neuronal networks, decreased the dendritic length and spine density. However, pretreatment with MJ improved motor deficits, increased TH activity and dopamine contents in the specific brain regions of Rot-treated rats. MJ also attenuated the cyto-architectural distortions, loss of neuronal cells and dendritic aborizations of the striatum of Rot-treated rats. These findings suggest that MJ may reverse the motor deficits associated with PD by modifying the key pathological abnormalities involved in the disease progression.
KeywordsMethyl jasmonate Rotenone Motor deficits Tyrosine hydroxylase Dendritic neuronal aborizations
Authors thank the technical staff of the Department of Pharmacology and Therapeutics for their assistance. We wish to thank Dr. A.O. Odeseye of the Department of Microbiology and Biotechnology, Nigeria Institute of Science Laboratory Technology (NISLT) for his technical assistance during the immunohistochemistry studies. We also thank Professor O.G. Ademowo, who introduced MJ to us.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Agrawal SS, Gullaiya S, Dubey V, Singh V, Kumar A, Nagar A, Tiwari P (2012) Neurodegenerative shielding by curcumin and its derivatives on brain lesions induced by 6-OHDA model of Parkinson's disease in albino Wistar rats. Cardiovasc Psychiatn Neurol 2012:942–981Google Scholar
- Bhullar KS, Rupasinghe HP (2013) Polyphenols: multipotent therapeutic agents in neurodegenerative diseases. Oxidative Med Cell Longev 89:17–48Google Scholar
- Cesari IM, Carvalho E, Rodrigues MF, Mendonça BS, Amôedo ND, Rumjanek FD (2014) Methyl jasmonate: putative mechanisms of action on cancer cells cycle, metabolism, and apoptosis. Int J Cell Biol 2014:1–25Google Scholar
- Dang HT, Lee HJ, Yoo ES, Hong J, Bao B, Choi JS, Jung JH (2006) New jasmonate analogues as potential anti-inflammatory agents. Bioorg Med Chem 16:10228–10235Google Scholar
- Demole E, Lederer E, Mercier D (1962) Isolementet determination de la structure du jasmonate de methyl, constituent odoerantcaracterisque de l'essence de jassmin. Helvetica Chimica Acta 45:675–685Google Scholar
- Deutch AY, Colbran RJ, Winder DJ (2007) Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism. Parkinsonism Relat Disord 13:251–258Google Scholar
- Dhanalakshmi C, Janakiraman U, Manivasagam T, Justin TA, Essa MM, Kalandar A, Khan MA, Guillemin GJ (2016) Vanillin attenuated behavioural impairments, neurochemical deficts, oxidative stress and apoptosis against rotenone induced rat model of Parkinson's disease. Neurochem Res 41:1899–1910PubMedGoogle Scholar
- Johnson IME, Salvatore MF, Maiolo SA, Bobrovskaya L (2018) Tyrosine hydroxylase as a sentinel for central and peripheral tissue responses in Parkinson’s progression: evidence from clinical studies and neurotoxin models. ProgNeurobiol 165–167:1–25Google Scholar
- Lee HJ, Maeng K, Dang HT, Kang GJ, Ryou C, Jung JH, Kang HK, Prchal JT, Yoo ES, Yoon D (2011) Anti-inflammatory effect of methyl dehydrojasmonate (J2) is mediated by the NF-κB pathway. J Mol Med (Berl) 89:83–90Google Scholar
- Ojha S, Javed H, Azimullah S, AbulKhair SB, Haque ME (2015) Neuroprotective potential of ferulic acid in the rotenone model of Parkinson’s disease. Drug Des Dev Ther 9:5499–5510Google Scholar
- Sawada M, Imamura K, Nagatsu T (2006) Role of cytokines ininflammatory process in Parkinson’s disease. J Neural Transm 70:373–381Google Scholar
- Sherer TB, Kim JH, Betarbet R, Greenamyre JT (2003b) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. ExpNeurol 179:9–16Google Scholar
- Stephens B, Mueller AJ, Shering AF, Hood SH, Taggart P, Arbuthnott GW, Bell JE, Kilford L, Kingsbury AE, Daniel SE, Ingham CA (2005) Evidence of a breakdown of corticostriatal connections in Parkinson’s disease. Neurosi 132:741–754Google Scholar
- Tendilla-Beltrán H, Vázquez-Hernández AJ, Agarcés-Ramírez L, Gonzaloflores G (2019) Exploring the dendritic spine pathology in a schizophrenia-related neurodevelopmental animal model. Neurosci 396:36–45Google Scholar
- Umukoro S, Eduviere AT (2017) Methyl jasmonate attenuates memory dysfunction and decreases brain levels of biomarkers of neuroinflammation induced by lipopolysaccharide in mice. Brain Res Bull 131:133–141Google Scholar
- Xu G, Xiong Z, Yong Y, Wang Z, Ke Z, Xia Z, Hu Y (2010) Catalpol attenuates MPTP induced neuronal degeneration of nigralstriatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum. Neurosci 167:174–184Google Scholar
- Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, Samii A, Deutch AY, Montine TJ (2005) Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurol 64:545–547Google Scholar